PEA
Palmitoylethanolamide
Naturally occurring fatty acid that supports pain relief and reduces inflammation through the endocannabinoid system.
PEA is a fatty acid amide naturally produced by the body that acts on the endocannabinoid system without being a cannabinoid itself. It has been studied extensively in Europe for chronic pain, inflammation, and neuroprotection. Works through multiple pathways to reduce pain signaling and inflammation, making it a promising natural option for pain management.
Mechanisms of Action
PPAR-α Activation
Activates nuclear receptors that reduce inflammation
Mast Cell Modulation
Calms overactive immune cells
Endocannabinoid Support
Supports the body's endocannabinoid system
Recommended Dose
600-1200mg
Optimal Timing
- With meals
- Split into 2-3 doses
Take with food
Best Form
Micronized or ultra-micronized PEA
Alternatives: Standard PEA powder, Levagen+ (cold-water dispersible)
Standard PEA has poor absorption. Micronized forms are much better absorbed.
Duration
Minimum: 4 weeks
Optimal: 8 weeks
Cycling: Not required
Note: Micronized forms absorb better. Split dosing maintains more consistent levels.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Pain Reduction
Significant decrease in chronic pain
Reduced Inflammation
Lower inflammatory markers
Neuroprotection
May protect nerve cells
Insufficient data; consult doctor
Who Should NOT Take This
- Known allergy or hypersensitivity to PEA or related compounds
Drug Interactions
Generally safe with medications
Possible Side Effects
Tip: Take with food
Warnings
- Use micronized forms for better absorption
- May take several weeks to see full benefits
Curcumin
complementaryBoth reduce inflammation through different pathways
Enhanced natural pain and inflammation relief
Omega-3
complementaryPEA is a fatty acid amide; omega-3s support similar pathways
Comprehensive anti-inflammatory support
Luteolin
complementaryBoth reduce mast cell activity
Synergistic anti-inflammatory and mast cell stabilization
Top studies from 40+ peer-reviewed papers
Schweiger V et al. • Nutrients (2024)
“Overall, these results confirm the clinically relevant and time-depended pain-relieving effect of micron-size PEA and therefore the advantage of an extended treatment, especially in patient with incomplete pain management.”
Key Findings:
- These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month.
- The meta-analysis showed a statistically and clinically significant pain intensity reduction after 60 days of micron-size PEA supplementation, compared to 30 days (1.36 points, p < 0.01).
- The secondary analysis revealed a weighted NRS/VAS score decrease of 2.08 points within the first month of treatment.
- Overall, these results confirm the clinically relevant and time-depended pain-relieving effect of micron-size PEA and therefore the advantage of an extended treatment, especially in patient with incomplete pain management.
Lang-Illievich K et al. • Nutrients (2023)
“Further study is warranted to determine the optimal dosing and administration parameters of PEA for analgesic effects in the context of chronic pain.”
Key Findings:
- PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001).
- Several studies reported additional benefits of PEA for quality of life and functional status, and no major side effects were attributed to PEA in any study.
- The results of this systematic review and meta-analysis suggest that PEA is an effective and well-tolerated treatment for chronic pain.
- Further study is warranted to determine the optimal dosing and administration parameters of PEA for analgesic effects in the context of chronic pain.
Bahji A et al. • Journal of psychopharmacology (Oxford, England) (2025)
“This study underscores the efficacy and tolerability of several pharmacotherapies in managing agitation among children and adults with ASD or ID.”
Key Findings:
- Importantly, these treatments were generally well-tolerated, with no significant increase in all-cause dropouts compared to placebo, highlighting their suitability for clinical use in managing agitation in individuals with ASD or ID.
- This study underscores the efficacy and tolerability of several pharmacotherapies in managing agitation among children and adults with ASD or ID.
- Our findings provide robust evidence that specific treatments, such as arbaclofen, risperidone plus buspirone and omega-3 fatty acids, are both effective and well-tolerated, offering valuable therapeutic options for clinicians.
- The study emphasizes the need for ongoing research to ensure that treatment strategies remain aligned with the evolving clinical landscape, ultimately improving patient outcomes in this challenging population.
Viña I et al. • Nutrition reviews (2025)
“This meta-analysis confirmed that PEA effectively reduces pain and enhances quality of life, with significant benefits observed within 4-6 weeks of treatment.”
Key Findings:
- This meta-analysis confirmed that PEA effectively reduces pain and enhances quality of life, with significant benefits observed within 4-6 weeks of treatment.
- Palmitoylethanolamide is a promising alternative to chronic opioid analgesics, potentially reducing the risk of opioid abuse and dependency.
- Further research warranted to confirm findings
Yang TK et al. • Clinical & experimental ophthalmology (2025)
“This study revealed PEA as a promising agent for long-term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy.”
Key Findings:
- Both brimonidine and unoprostone isopropyl have SUCRA scores below 4.0%, indicating modest but limited efficacy.
- Brovincamine has the lowest SUCRA score (1.32%), reflecting minimal effectiveness.
- This study revealed PEA as a promising agent for long-term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy.
- The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long-term efficacy and safety for NTG.
Study Type Distribution
Goals This Supplement Supports
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.